Peer Review Committee for Tumor Biology and Genomics (TBG)

Areas reviewed

  • In vivo tumor models
  • oncogenes and tumor suppressor genes in vivo
  • gene target validation
  • drug efficacy testing
  • human genetics/genomics
  • pharmacogenetics
  • pharmacogenomics
  • genetic risk
  • genotype to phenotype
  • gene therapy testing,
  • biomarker identification/development

Committee Members

Jonathan Brody, PhD, Chair
Thomas Jefferson University
Philadelphia, PA

Scott A. Gerber, PhD, Vice-Chair
Dartmouth College
Lebanon, NH

Kevin M. Brown, PhD
National Cancer Institute
Bethesda, MD

Lara Collier, PhD
University of Wisconsin – Madison
Madison, WI

David Dawson, MD, PhD
University of California, Los Angeles
Los Angeles, CA

Dan G. Duda, PhD
Massachusetts General Hospital
Boston, MA

Michael E. Engel, MD, PhD
University of Utah
Salt Lake City, UT

Robert Gooze, Stakeholder
Oregon, WI

Lata Jayaraman, PhD
Seres Therapeutics
Cambridge, MA

Peggy Kupres, Stakeholder
Frankfort, IL

Sandra McAllister, PhD
Brigham and Women’s Hospital
Boston, MA

Nicholas Mitsiades, MD, PhD
Baylor College of Medicine
Houston, TX

Goutham Narla, MD, PhD
University of Michigan
Ann Arbor, MI

Trudy G. Oliver, PhD
Huntsman Cancer Institute, University of Utah
Salt Lake City, UT

Kristy L. Richards, PhD, MD
Cornell University
Ithaca, NY

Devanand Sarkar, MBBS, PhD
Virginia Commonwealth University
Richmond, VA

Christopher Willey, MD, PhD
University of Alabama
Birmingham, AL